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Thalassemia syndrome has diverse clinical presentations and a global spread that has far exceeded the classical
Mediterranean basin where the mutations arose. The mutations that give rise to either alpha or beta thalassemia
are numerous, resulting in a wide spectrum of clinical severity ranging from carrier state to life-threatening,
inherited hemolytic anemia that requires regular blood transfusion. Beta thalassemia major constitutes a remarkable
challenge to health care providers. The complications arising due to the anemia, transfusional iron overload, as well
as other therapy-related complications add to the complexity of this condition. To produce this consensus opinion
manuscript, a PubMed search was performed to gather evidence-based original articles, review articles, as well as
published work reflecting the experience of physicians and scientists in the Arabian Gulf region in an effort to
standardize the management protocol.
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TransfusionIntroduction
Thalassemia is a group of inherited disorders that arise
as a result of certain mutations in hemoglobin (Hb)
genes, affecting the makeup of Hb in the red blood cells,
which leads to certain pathophysiological disorders [1].
The genetic disorder is characterized by the absolute or
partial synthesis of one or more alpha (α)- or beta (β)-
globin chains [2,3]. The types of β-thalassemia are called
major, intermedia, and minor. β-Thalassemia major is
caused by a defect in 2 genes that leads to absence or a
severe decrease in β-globin synthesis. β-Thalassemia
intermedia is a clinical phenotype with moderate anemia
and transfusion independence. Genetically it results
from mutations in the 2 β genes resulting in mild to
moderate decrease in their synthesis. β-Thalassemia
minor, or thalassemia trait, occurs when the defect is
present in only 1 gene [2].* Correspondence: shaker.mousa@acphs.edu
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reproduction in any medium, provided the orβ-Thalassemia carriers comprise 1.5% of the world-
wide population, with an estimated 60,000 infants with
a serious defect being born every year [1]. In the
United States, approximately 1,000 individuals have β-
thalassemia major, the most severe form of thalassemia
[4]. It is most commonly found in people of Mediterra-
nean descent, such as Italians and Greeks, but also af-
fects people from other parts of the world such as
Africa, the Middle East, the Indian subcontinent, and
Southeast Asia [2,5].
Blood transfusions are often required to treat patients
with thalassemia major, who are transfusion-dependent
and frequently need to receive 2 to 4 units per month of
packed red blood cells [6]. Patients with β-thalassemia
major require transfusions throughout life to achieve the
target Hb level in the range 9 to 10 g/dL and to promote
normal growth [7,8]. Iron overload can develop in
transfusion-dependent patients as a result of non-
removal of excess iron. High iron concentration load can
cause complications due to iron deposition in organs
such as the heart, liver, and endocrine glands.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Thalassemia is the most common form of inherited
anemia worldwide [9]. It occurs with a high frequency in
a broad belt extending from the Mediterranean basin
through to the Middle East, Indian subcontinent, and
Southeast Asia [10]. Thalassemia is a growing global
health problem due to extensive population migrations.
About 3% of the world population (about 200 million
people) are carriers of the β-thalassemia gene [11].
The incidence of β-thalassemia in Arabian Gulf coun-
tries is not clearly known due to lack of mandatory
screening programs [12-16]. The majority of data were
obtained from scattered screening studies using Hb
electrophoresis as summarized in Table 1.Pathophysiology
β-Thalassemia is a group of heterogeneous autosomal
recessive disorders arising due to the absence or reduced
synthesis of the β-globin chain [18]. β-Thalassemia could
be associated with severe congenital disorders caused by
mutations in the β-globin gene resulting in the absence
or reduced synthesis of the β-globin chain [1,12]. This
deficit of β-globin chains leads to precipitation of excess
α-globin chains resulting in the formation of inclusion
bodies, which contribute to hemolysis of red blood cells.
Hematological changes are manifested between the ages
of 3 months and 6 months onwards [13]. Over 200 dif-
ferent mutations have been elucidated worldwide, and
the mutations are population-specific. In the Middle
East, codon 39 (C > T), IVSI-110 (G > A), IVSI-1 (G > A),
IVSI-6 (T > C), IVSII-1 (G > A), codon 5(−CT), and
IVSI-5 (G > C) mutations account for more than 90% of
β-thalassemia mutations in the region. However, these
mutations differ in numbers and frequencies between
different populations of the Middle East. Over 50 differ-
ent mutations have been identified in the Arab popula-
tions, reflecting the heterogeneity of these populations
[19,20]. The molecular spectrum of β-thalassemia in the
Arab populations of Jordan, Egypt, Syrian Arab Republic,
Lebanon, Yemen, and Saudi Arabia revealed that the
most frequent mutations were: IVS-1-5 (G–C), IVS-II-1
(G–A), IVS-1-1, Fr 8/9, Fr 41/42, Cd 15, Cd 16, Cap +1Table 1 Estimated prevalence of β-thalassemia (minor
and major) in Arabian Gulf countries
Country Minor (%) Major (%) Reference
Saudi Arabia 3.4 NA* [12]
Bahrain 0.88 0.16 [13]
Qatar 28 0.07 [14]
United Arab Emirates 1.7 NA* [15]
Oman 2 0.04 [16,17]
* Not available.(A–C), IVS-1-110, IVS-1-3′ end (−25 bp) and IVS-1-6
[21-23].
Presentation and diagnosis
β-Thalassemia comprises a complex spectrum of clinical
presentations. The clinical phenotype is influenced by
the genetic phenotype and other modifiers. The basic
disease is caused by the inability to produce normal β-
globin chain with the consequence of excess α-chain,
leading to disruption of the α:β ratio, which in turn will
cause various cellular and clinical syndromes [1,24].
β-Thalassemia is clinically classified into 4 subtypes
(Table 2):
1. β-thalassemia silent carriers; asymptomatic, one β-
globin chain is normal and the other is partially
defective (ββ+).
2. β-thalassemia trait; one β-chain is totally defective
and the other is normal (ββ°). These patients have
mild anemia, and <20% have palpable spleen [25,26].
3. β-thalassemia intermedia; this term is useful
clinically, but does not correlate with its genetic or
clinical mechanism for the phenotype [27,28];
usually used to describe β-thalassemia patients who
do not require chronic red cell transfusion in early
childhood, although by the second decade of life
they may present the same picture as β-thalassemia
major [28]. Most of the patients have homozygous
partial production defect of β globin β+β+ or β+β°,
and there are many co-inheritance factors that
influence the clinical spectrum (Table 1). Patients
with β-thalassemia intermedia frequently develop
moderate to severe skeletal changes because of bone
marrow expansion, osteoporosis, leg ulcers,
gallstones, and pulmonary hypertension and have an
increased predisposition to thrombosis as compared
to thalassemia major [29-33]. Cardiac involvement
in thalassemia intermedia results mainly from a
high-output state and pulmonary hypertension,
while systolic left ventricle function is usually
preserved [31]. These patients have a spectrum of
severity, but all have complications in common:
a. Chronic anemia: high cardiac output, increased
pulmonary vascular resistance, pulmonary
hypertension, and heart failure
b. Iron overload: because the patients are not
receiving chronic transfusion, there is increased
gut iron absorption with subsequent symptoms
and signs of iron overload
Treatment of individuals with thalassemia
intermedia is symptomatic [33]. As hypersplenism
may cause worsening anemia, retarded growth, and
mechanical disturbance from the large spleen,
splenectomy is recommended. Prevention of post-
Table 2 The phenotype and genotypes of β-thalassemia
Phenotypes Genotype MCV Anemia Hb electrophoresis
Silent carrier ββ+ Low/Normal None Normal
Minor (Trait) ββ° Low Mild High Hb A2
Intermedia β+β+ and others Low Moderate Presence of small amount of A and could be similar to Major
Major β°β° Low Severe Hb A absent, only Hb A2 and Hb F are present
HB hemoglobin, Hb A adult hemoglobin, Hb F fetal hemoglobin, MCV mean corpuscular volume.
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and antibiotic prophylaxis. The gallbladder should
be inspected during splenectomy and removed in all
cases to prevent gallstones. Treatment of extra-
medullary erythropoietic masses, detected by
magnetic resonance imaging, is based on
radiotherapy, transfusions, or hydroxycarbamide.
Leg ulcer requires regular blood transfusions, zinc
supplementation, hydroxycarbamide, pentoxifylline,
and possibly erythropoietin and platelet-derived
growth factor. The high risk of thrombosis,
exacerbated by splenectomy, requires proper
anticoagulation and/or antiplatelet agents prior to
surgical or other high-risk procedures. Chelation
therapy is essential to prevent iron overload. In
some Arabian Gulf countries, patients with known
thalassemia intermedia mutations (e.g., Hb Dhofar)
are regularly hyper-transfused from the beginning to
avoid the serious complications of excessive
medullary and extra-medullary haematopoiesis
[34,35].
4. β-thalassemia major (transfusion-dependent β-
thalassemia); total impairment of β-globin chain
production leading to excess α-globin chain, which
in turn is unable to form soluble tetramers and is
precipitated in the cell, leading to a sequence of
cellular and clinical events. These patients are well
at birth, and the clinical picture will start after the
fetal Hb (Hb F) switch to adult Hb (Hb A) fails
because there is no β-chain produced, leading to
anemia, which usually starts after 6 months of age.
The severity of phenotype is heterogeneous
depending on the type of mutation influencing the
β-chain production, e.g., β°, β+, the balance between
α- and β-chain and Hb F production
[27,29,30,36-39]. The manifestations in untreated
patients include pallor, irritability, cardiac failure,
growth failure, hepato-splenomegaly, bone
abnormality, and features of hemolysis. The majority
of untreated patients under the age of 5 years die
due to anemia, heart failure, or infections [27,40-45].
The patients who have severe β-thalassemia develop
symptoms in the first year of life with progressive
anemia, failure to thrive, poor feeding, intermittentbouts of infection, and general malaise in most cases.
These infants are pale and, in many cases, splenomegaly
is already present. A few patients might present as late
as between the third to fifth year of age [27,30,46]. The
diagnosis of β-thalassemia requires a patient history,
physical examination, and confirmatory laboratory tests
including complete blood count and blood film morph-
ology, both demonstrating microcytic hypochromic
anemia, and confirmation by alkaline Hb electrophoresis
(Table 2) [46].
The features of the different presentations of thalassemia
syndromes are:
1. β-thalassemia silent carrier
 Normal phenotype
 Laboratory: normal Hb, RBC indices, and Hb
electrophoresis
2. β-thalassemia minor (trait)
 Haematocrit >30%
 Hb and peripheral morphology similar to iron
deficiency state
 RBC count more than normal, MCV is low
 RDW is normal
 Hb electrophoresis or HPLC show elevated Hb
A2 (except in rare cases will be normal)
3. β-thalassemia intermedia
 Hb is low (6-10 g/dL)
 CBC and peripheral morphology are variable
with hypochromic, microcytic changes with
variation in RBC size and shape
 RDW is increased
 Hb electrophoresis or HPLC show different
patterns; some patients are able to produce Hb A
in small quantities or similar to homozygous β-
thalassemia zero where Hb A is absent
4. β-thalassemia major
 CBC:◦ False elevated WBC because of
nucleated RBC
◦ Severe anemia with Hb as low as 3-4 g/dL
◦Microcytic hypochromic picture with
fragmented RBC, tear drops, target cells, and
RBC with inclusion bodies
 Reticulocyte count low
 Serum iron to TIBC is high
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as Hb F and Hb A2 (Table 2)The final step in a diagnostic approach is to perform
DNA studies on the genetic material extracted from per-
ipheral blood. This will identify the type of the mutation
and help identify the silent carriers [18].
Transfusion therapy in thalassemia
Red cell transfusions are required to increase the
oxygen-carrying capacity of the blood through raising
the Hb concentration of patients with acute or chronic
anemia [1]. Guidelines for the transfusion of blood and
blood components and the management of transfused
patients are in accordance with the British Committee
for Standards in Haematology [47]. The major goals for
blood transfusion therapy include [48,49]:
1. Maintenance of red cell viability and function during
storage to ensure sufficient transport of oxygen
2. Use of donor erythrocytes with a normal recovery
and half-life in the recipient
3. Achievement of appropriate Hb level
4. Avoidance of adverse reactions, including
transmission of infectious agents.
Current practice and recommendation for transfusion
therapy in Arabian Gulf countries
The recommended treatment for thalassemia major
involves lifelong, regular blood transfusions, usually
administered every 2 to 5 weeks to maintain the pre-
transfusion Hb level above 9.5-10.5 g/dL [50,51]. How-
ever, in most of the Gulf countries, 9 g/dL is accepted as
the minimum pre-transfusion Hb level. Higher levels
(11–12 g/dL) may be needed for patients with cardiac
complications. The post-transfusion Hb is kept not
higher than 14–15 g/dL.
Our practice includes extended red cell antigen typing
of patients including C, E, and Kell before the first trans-
fusion. At each transfusion, we do a full cross match and
screening for the new antibodies. Matching for C, E, and
Kell antigens is only done for negative patients. The
blood is leuko-reduced with pre-storage filtrations. Some
countries also practice bed-side filtrations. Transfusion
is attended by nurses who report any adverse reactions.
Blood that has not been transfused by 4 hours after
hooking is discarded.
Iron overload
During the introduction of a regular transfusion pro-
gram in the early 1960s, an iron chelating agent demon-
strated improved survival. However, iron overload is still
one of the most critical issues, and its complications re-
main the most important cause of morbidity andmortality [52,53]. In addition, the lack of adherence to
an iron chelating agent regimen is considered an import-
ant factor in suboptimal clinical improvement and poor
prognosis [54]. Many significant developments have
been made in the assessment of iron overload, and ad-
vances in the modalities available for iron chelation have
expanded treatment options and improved treatment
management.
In a chronically transfused patient, one unit of blood
contains 200 mg iron [55]. Since humans have no
physiologic mechanism for active elimination of excess
iron, patients receiving regular RBC transfusions de-
velop cumulative iron overload and are at risk for iron
toxicity [55].
In addition to the transfused iron, thalassemia patients
absorb more iron than normal individuals. The mechan-
ism of increased absorption in thalassemia patients is
thought to be related to paradoxical Hepcidin suppres-
sion from dys-erythropoiesis [56]. Free iron is subse-
quently deposited primarily in parenchymal cells of
different organs. Then it will participate in oxidative re-
actions to generate free oxygen radicals, which can lead
to chronic cell toxicity and DNA damage [57].
Measurements of iron load
Parameters used to monitor iron load include serum fer-
ritin, liver biopsy, and MRI assessment of liver and car-
diac iron, in conjunction with functional testing such as
echocardiography, liver function test, and measures of
endocrine function.
Serum ferritin
Serum ferritin is the most commonly used parameter for
monitoring iron overload despite its inaccuracy and limi-
tation in assessing the body iron overload. It is a valu-
able method to roughly assess the long-term, overall
status of iron overload and to monitor response to che-
lation therapy. It is also valuable due to its ease of meas-
urement and wide availability, and it correlates with
cardiac impairment and survival but not with hepatic
iron [58]. Serum ferritin is elevated in many other condi-
tions such as infections, inflammation, or malignancy.
Iron overload is generally defined as serum ferritin con-
sistently ≥ 1000 ng/L [59]. It is recommended to know
the baseline level of ferritin and to assess the trend by
taking serial measurement of serum ferritin every 3
months. In the Gulf area, due to the wide availability of
the test in all treating centers, the test is done on a
monthly basis.
Liver biopsy
Liver iron concentration remains the most accurate
measure of total body iron loading [60], and liver biopsy
was previously considered to be the gold standard of
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ciated with a risk of complications. Liver biopsy is still
performed to evaluate liver fibrosis, cirrhosis, or hepato-
cellular carcinoma, which are possible complications in
all patients with liver iron overload. It is well known that
a hepatic iron level of 7–15 mg/g dry weight is associ-
ated with an increased risk of complications; a higher
level increases risk of cardiac disease and early death.
However, because of its invasive nature and lack of cul-
tural acceptance, this test is rarely performed in the Gulf
area centers.
MRI assessment of liver iron
MRI is the method of choice in the monitoring of vari-
ous organs’ iron levels where the measurement of tissue
proton transverse relaxation rates (R2) was shown to
have excellent correlation with liver iron concentration
measured by biopsy [61]. An annual monitoring of R2
MRI is recommended, which can be extended to every 2
years for patients with normal liver iron or at the lower
end of the ideal iron range of less than 7 mg/g dry
weight. Additionally, liver iron levels should also be
correlated with standard liver function tests.
MRI assessment of cardiac iron
Similar to liver iron measurement, MRI has been widely
used to annually monitor iron levels in the heart whereTable 3 Comparative analysis of different iron chelators
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Biliary and urinary Urinary
Regulatory
approval
US, Canada, Europe, other countries US, Europe






Irritation at the infusion site, ocular and
auditory disturbances, growth retardation and
skeletal changes, allergy, respiratory distress







Inexpensive/ Compliance Route of athe measurements of T2*, a relaxation parameter intrin-
sic to protons placed in the magnetic field, is utilized
[62]. In the Gulf region, very few centers have this tool
available. It is recommended to expand this service for
thalassemia patients because MRI is a noninvasive,
reliable, and accurate method of assessing iron overload.
Chelating agents
There are 3 main available chelators: deferoxamine,
deferiprone, and deferasirox (Table 3); deferiprone and
deferasirox are oral chelators that have come into the
clinic in recent years. They are different in molecular
weight, leading to differences in intestinal absorption.
For several decades, the only available iron chelator was
deferoxamine [58].
In the Gulf region, deferoxamine has been available
since the early 1970s, and nowadays it is much less
widely used except in combined chelation therapy. In
1999, deferiprone was introduced to Oman and has been
widely used as monotherapy or combined therapy. In
other Gulf States it was introduced in early 2000s. Al-
though the international guidelines recommend the use
of deferiprone after the age of 6 years, in some Arabian
Gulf countries the syrup formulation has been widely
used with good efficacy for children 2 years and above
with no serious complications. In a recent study,
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liver enzyme levels, low plasma
hepatic fibrosis
Gastrointestinal disturbances, rash,
increase in serum creatinine level;
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or failure
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with progression to agranulocytosis [63]. We recom-
mend giving extensive counseling to the patients, with
clear instructions to report to hospital emergency in case
of fever and to have an urgent CBC with ANC count.
Deferasirox has been available in the Gulf area since
2007. It has been widely used across all the Gulf coun-
tries. Side effects are comparable (Table 3) to those pub-
lished in the literature [64], and its efficacy has been
demonstrated in many clinical trials [65]. It is used only
as monotherapy. Some patients do not respond to the
maximum dose of 40 mg/kg/day, however, and compli-
ance may be an issue with this drug, just as it is for the
other available chelators.
Hematopoietic stem cell transplantation (HSCT) for
thalassemia
HSCT has the potential to be curative for thalassemia
major and has been increasingly adopted, with cautions.
The first two cases of HSCT for thalassemia were
performed in 1981, one in Seattle, Washington, and the
other in Pesaro, Italy [66]. Since 1981, a large clinical ex-
perience has been gained with more than 2,000 HCSTs
in centers around the world. The patient classes have
been identified on the basis of 3 risk factors (the Pesaro
classification): inadequate iron chelation therapy, pres-
ence of liver fibrosis, and hepatomegaly (Table 4) [67].
Factors to be taken into consideration for HSCT in
thalassemia
Age
Since gonadal damage occurs with the myeloablative
conditioning regimens currently used in thalassemia
transplants, it is important to try to perform transplant
as early as possible to minimize infertility. An age range
of 2–5 years may seem reasonable [68]. For several rea-
sons an earlier patient age at transplant has a better
outcome because a fewer number of transfusions
(allosensitization) would decrease the chances of rejec-
tion, and complications of iron overload and organ andTable 4 Stem cell transplantation for thalassemia
Class I Class II Class III
Number of risk factors None 1-2 3
Survival (%) 93 87 79
Event free survival (%) 91 83 58









GVHD graft-versus-host disease.transplant-related toxicity will be less. Accordingly,
tolerance for myeloablative conditioning regimens
would be better compared with older age groups and
adults [68,69].
Conditioning
The standard conditioning regimen that is practiced in
most HSCT units all over the world, especially for class
I and II patients, consists of busulfan and cyclophospha-
mide and GVHD prophylaxis in the form of cyclosporine
A and methotrexate [70,71]. New developments in con-
ditioning regimens have taken place over the last decade.
The introduction of IV busulfan with drug level moni-
toring and IV fludarabine improved the efficacy and re-
duced the toxicity of transplant outcome [72]. In
addition, HSCT outcome for patients of older age with
advanced disease receiving a second transplant improved
markedly with improved pre-transplantation preparation
and simultaneous use of myeloablative and prolonged
immune suppression. In order to be utilized effectively
and to minimize toxicity and rejection, it is important
that busulfan levels are monitored and doses adjusted
accordingly [72,73]. Several centers have recently
reported using new therapeutic conditioning regimens
utilizing the combination of treosulfan, thiotepa, and
fludarabine because treosulfan does not require thera-
peutic drug monitoring. The outcome of the new regi-
men may be effective and safer even for more advanced
thalassemia and may replace busulfan as the condition-
ing of choice [74,75].
Matched umbilical cord as stem cell source
While HSCT from a bone marrow harvest of a fully
HLA-matched donor is the recommended option, genet-
ically matched umbilical cord blood can be a suitable
source [76]. This provides an alternate source of stem
cells with minimal risk to the donor. In the Gulf area,
experience with this form of HSCT is still very limited.
Results of HSCT for thalassemia in the Gulf area
Two countries are doing HSCT, namely Oman and
Saudi Arabia. Between 1996 and 2010, a total of 47 pa-
tients with thalassemia major underwent matched sib-
ling donor HSCTs in Oman. Most received busulfan and
cyclophosphamide with or without ATG, while more re-
cently patients received busulfan and fludarabine.
Eighty-nine percent are alive and free from thalassemia
at a median follow-up of 125 months (22–197 months).
Graft rejection was 8.5%, and transplant-related
mortality was 4.3% [77].
In Saudi Arabia, transplants in 60 thalassemic patients
were done between January 1998 and July 2006 from
HLA-related, matched donors. The overall survival and
event-free survival were 94% and 77%, respectively [69].
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Iron overload can be either from thalassemia itself or from
frequent blood transfusions. The damage is characterized
by excessive iron deposition without adequate iron chela-
tion therapy; almost all patients with β-thalassemia will
accumulate potentially fatal iron levels [78]. A range of
complications including endocrinopathies, hypersplenism,
infertility, hepatobiliary, musculoskeletal, and cardiopulmo-
nary can arise. Complications are linked to overstimulation
of the bone marrow, dysfunctional erythropoiesis, an
increase in iron burden, imbalance of oxidant/antioxi-
dant ratio, and chelation of essential elements such as
zinc.
Endocrinopathies
Endocrinopathies are characterized by poor growth; de-
layed puberty, infertility, and impaired glucose tolerance
are some complications that can occur in thalassemia
patients [79-81]. Hypogonadism is a common complica-
tion that occurs due to a high iron burden [82-85].
Endocrine complications arise possibly due to factors
that influence the anterior pituitary gland, which might
be due to free radical oxidative stress damage for the
pituitary and hypothalamus leading to growth hor-
mone deficiency, resulting in delayed growth and
infertility [85,86].
Early and appropriate management is crucial in β-
thalassemia patients, and hormone therapy is an effect-
ive option in the management of hypogonadism [87].
Hormone therapy to young β-thalassemia patients with
low iron burden can induce increases in height, growth,
and stimulate puberty [83,88]. Initiating aggressive and
appropriate chelation therapy is important along with
hormone therapy to minimize iron deposition in the
endocrine glands. Along with hormone therapy, zinc
supplementation is recommended in patients who have
growth impairment and low serum zinc levels [85,89].
Hypersplenism
Hypersplenism is another complication in patients who
have either thalassemia major or thalassemia intermedia,
leading to compromised immune function. It is associ-
ated with leukopenia, thrombocytopenia, and increased
requirement for transfusions. Splenomegaly (enlarged
spleen) develops in these patients, often requiring a
splenectomy, which is conducted to reduce the need for
red cell transfusion [89-92].
Infertility/pregnancy
In women with β-thalassemia, infertility is a common
issue due to iron deposition and oxidative damage to
endocrine organs as a result of blood transfusions. How-
ever, with advances in the management of thalassemia,
chances of conceiving have increased and pregnancy hasbecome more prevalent, but pregnancy is not
recommended in women who have cardiac dysfunction
[93]. For women who are at high risk of iron overload
and who intend to conceive, an echocardiography is
recommended before conception and during pregnancy
to evaluate cardiac function [94].
Management of pregnant women with thalassemia
major requires blood transfusions and maintaining a Hb
level of at least 10 g/dL [93]. According to the American
Congress of Obstetricians and Gynecologists (ACOG)
guidelines, iron chelation therapy with deferoxamine is
not recommended during pregnancy because its safety
has not been well established [93,95]. For patients who
are at high risk of increased iron deposition in the heart
and liver, oral chelation therapy should be used with
caution [95]. Administration of deferasirox to animals
during pregnancy and lactation resulted in reduced off-
spring viability [96]. It is important to note that the oral
chelator deferiprone is a fairly small molecule that can
cross the placenta, and therefore it is contraindicated in
pregnancy [97]. After pregnancy, patients can resume
iron chelation therapy.Hepatobiliary disorders
It has been documented that within 2 years of transfu-
sion initiation, hepatocellular injury can occur when the
liver iron concentrations exceed normal levels, leading
to tissue damage, collagen formation, and portal fibrosis
[98]. Furthermore, in the presence of infections such as
hepatitis C virus infection, there is increased risk of the
development of liver fibrogenesis. Reducing iron burden
would reduce liver fibrosis and improve survival in β-
thalassemia patients since liver iron concentrations
greater than 7 mg/g dried weight are shown to be linked
to increased morbidity and mortality [98]. Furthermore,
β-thalassemia patients might potentially benefit from
combination therapy with iron chelators and green tea
extract to decrease the progression of liver fibrosis [99].Musculoskeletal
Patients with thalassemia may exhibit dramatic skeletal
abnormalities, frequently leading to marked structural
changes and delayed skeletal maturation, due to the ex-
pansion of erythroid bone marrow, which widens the
marrow spaces, attenuates the cortex and produces
osteoporosis. The skull and facial bones are often strik-
ingly abnormal, there is prominent frontal bossing, de-
layed pneumatization of the sinuses, and marked
overgrowth of the maxillae. Premature fusion of the
epiphyses can result in characteristic shortening of the
limbs, particularly the arms. Of equal concern is the thin-
ning of the cortices due to marrow expansion, which
often results in pathologic fractures [100].
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itional factors including iron deposit in bone, vitamin D
deficiency, and deferoxamine toxicity in bone. The inter-
actions among iron, hemopoietic cells, osteoblasts, and
osteoclasts in bone tissue have never been explained
[101,102]. There is now a growing awareness that many
transfusion-dependent adult patients with β-thalassemia
major and intermedia suffer from long-standing bone
pain, low bone mass, and fractures.
Current transfusion and chelation practices might be
insufficient to prevent the development of low bone
mass, and additional strategies to improve bone mineral
density are required. There is a need for clinical trials to
determine the appropriate form of hormone replacement
therapy along with vitamin D supplementation as other
strategies to optimize bone accrual in this disease. In
thalassemia patients with iron overload, regular assess-
ment of bone density from puberty every 2 years if
normal, and annually if abnormal, might be required.
Additionally, it is necessary to ensure adequate cal-
cium intake, sun exposure, and vitamin D intake.
Bisphosphonate therapy may be indicated if osteopor-
osis is documented [103].
Cardiopulmonary
Cardiopulmonary dysfunction represents one of the
most under-diagnosed complications. The main cardiac
abnormalities reported in patients with thalassemia
major and iron overload are left ventricular systolic and
diastolic dysfunction, pulmonary hypertension, ar-
rhythmias, and pericarditis. These cardiac abnormal-
ities are closely related to concomitant endocrine
deficiencies, thromboembolic events, and inflamma-
tory milieu [104,105].
Iron-induced cardiomyopathy is slowly progressive,
and it usually takes several decades for clinical or
laboratory features of cardiac dysfunction to manifest
[106-108]. Cardiac complications represent the leading
cause of mortality in thalassemia major with uncon-
trolled iron overload. Following the introduction of che-
lating therapies, an important and progressive increase
of life expectancy mainly due to improvement of cardiac
dysfunction has been demonstrated [106-108].
Pulmonary impairment is shown in a great proportion
of patients, even among asymptomatic young patients,
thus, regular screening of pulmonary function should be
adopted in the routine clinical follow-up of these pa-
tients [109]. Pulmonary hypertension is common in thal-
assemia and contributes to mortality. Advancing age and
a history of splenectomy are major risk factors in this
population. Guidelines for the management of pulmon-
ary hypertension in thalassemia have not yet been
established, however, clinical trials are ongoing in an ef-
fort to guide future therapy [90,110,111].Psychosocial impact
Psychosocial and behavioral problems are common in
thalassemia patients and their family, suggesting the
importance of lifelong psychosocial support [112].
Based on the conclusions of previous studies, it was
recommended that medical therapy of these patients
should be supported with psychological and psychiatric
therapy. Chronicity is a powerful source of emotional
problems that intensify at each significant developmen-
tal stage of the patient’s life. Patients can feel that they
are different, limited, or isolated. Their state of mind
can shift rapidly from depression to anger and vice
versa. Health workers must be prepared to accept this
shift and to help patients deal with these feelings and
to find their own way of normal life [113,114]. Se-
veral objectives have to be achieved to reach the goal
of optimal psychosocial integrity of the patients,
including:
1. Educate patients and parents to understand the
magnitude of the illness.
2. Provide support to patients to be able to take care of
themselves.
3. Facilitate a normal lifestyle and encourage patients
in ways to develop a normal adult life.
These objectives can be achieved by the support of a
well-trained, multidisciplinary team who understands
chronic hereditary diseases.
Future treatment options and prevention
Stem cell transplantation
Improvement in the life expectancy of patients with β-
thalassemia major is due to effective transfusion and
iron chelation therapy. However, the only current cura-
tive treatment is stem cell transplantation, which is be-
coming more utilized in good patient candidates, and
several centers are doing it in the Gulf States–in par-
ticular Saudi Arabia. Production of fetal Hb by cytotoxic
agents such as demethylation agents and hydroxyurea,
has been explored over the last two decades [115,116].
Prevention
Prevention of thalassemia is the only solution to effi-
ciently reduce the huge medical, social, and economic
impact in countries where it occurs with high frequency.
Premarital screening became mandatory for hemoglo-
binopathies in Saudi Arabia with the intention to
decrease the prevalence of the disease [115,117]. Pre-
implantation genetic diagnosis is an important option
for couples at risk of having children with β-globin mu-
tations [118]. Some premarital and antenatal screening
centers in the Gulf area refrain from aborting fetuses
owing to religious and cultural reasons. Public awareness
Qari et al. Orphanet Journal of Rare Diseases 2013, 8:143 Page 9 of 12
http://www.ojrd.com/content/8/1/143and related social activities are important tools to im-
prove the understanding of the burden of this disease
and of how to support preventive programs aiming to
eradicate this disease.Conclusions
The prevalence of thalassemia syndrome in the Ara-
bian Gulf area necessitates more work to estimate the
size of this health problem and its impact on the com-
munity and the quality of life of the patients and their
families. The rationale behind the interest in thalas-
semia is its responsiveness to treatment with regular
blood transfusion and the reversibility of complications
with iron chelation. In the Gulf States there is a great
potential for improving the quality of care provided to
thalassemia patients, hence this manuscript was pre-
pared to emphasize the importance of neonatal scree-
ning programs.
Efforts of the health care providers should be directed
to improve the early diagnosis and management of
β-thalassemia through enrolling the patients in a
Thalassemia Center of Excellence to ensure the max-
imum service and to prevent disease complications.
Pre-implantation genetic diagnosis is an option that has
become widely accepted religiously and socially to
prevent severe β-thalassemia in the Gulf Countries.Competing interests
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